Mirabegron Zentiva

Mirabegron, the active ingredient in Mirabegron Zentiva, is a Beta-3 adrenergic receptor agonist presented as an oral dosage form for oral use. It treats overactive bladder symptoms such as urgency, frequency, and urge urinary incontinence in adults.

GNH USA supplies Mirabegron Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirabegron is used to manage overactive bladder, a condition characterized by urinary urgency and frequency.

- Overactive bladder: increases bladder capacity and reduces urgency episodes. - Urinary urgency: lessens the frequency of sudden urges to void. - Urge urinary incontinence: decreases episodes of involuntary leakage.

Adverse reactions may occur with mirabegron therapy.

Common Side Effects: - Hypertension - Nasopharyngitis - Urinary tract infection - Headache - Constipation - Dry mouth

Serious or Rare Side Effects: - Severe hypertension - Urinary retention - Tachycardia - Angioedema - Myocardial infarction - Anaphylaxis

Before initiating mirabegron, several safety considerations should be reviewed.

- Monitor blood pressure: check baseline and periodically during therapy. - Assess renal function: adjust use in patients with severe impairment. - Review cardiovascular history: use cautiously in patients with arrhythmias. - Evaluate for drug interactions: avoid concomitant strong CYP2D6 inhibitors. - Store at room temperature: keep in the original container, protect from moisture and light.

Mirabegron may interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors: can increase mirabegron exposure. - Antihypertensive agents: additive blood‑pressure‑lowering effects.

Moderate Interactions (Monitor Closely): - Diuretics: may affect blood‑pressure control. - Anticholinergic agents: may reduce overall efficacy for overactive bladder. - CYP3A4 inducers: may lower mirabegron plasma concentrations.